IOPtima Ltd., a Chengdu Kanghong Pharmaceutical company is a developer of minimally-invasive surgical ophthalmic devices. The company’s flagship product, the IOPtimate™, is a surgical system for the treatment of Glaucoma. With a mission to address the unmet needs and common safety problems in glaucoma surgery, the company has developed a procedure named CLASS (CO2 Laser-Assisted Sclerotomy Surgery). In utilizing the particular properties of the CO2 laser, the IOPtimate thins the sclera wall via ablating surges at the normal eye drainage area (Schlemm’s Canal region), in a simple and highly controlled and specific manner. This elegant self-regulated procedure is possible because the IOPtimate system is designed to achieve functional, simple, safe, reproducible and optimal results from surgery, with minimal side effects and reduced recovery time. At the same time, the procedure is highly efficacious, with a minimal learning curve